Drugs / QAX576
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01568762 | Oct 2010 → Jul 2011 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00417196 | Dec 2006 → Aug 2007 | — | Novartis | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00598104 | Jan → Dec 2008 | asthma | Novartis | Withdrawn | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT01479595 | Feb 2012 → Feb 2015 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01355614 | Jun 2011 → Mar 2013 | Crohn disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01316601 | Jan 2011 → Nov 2012 | Crohn disease | Gerhard Rogler | Completed | No outcome recorded |
| Phase 2 | NCT01266135 | Dec 2010 → Apr 2013 | idiopathic pulmonary fibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01130064 | May 2010 → Apr 2012 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00987545 | Jun 2009 → Nov 2010 | keloid | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00584584 | Dec 2007 → Aug 2008 | allergic rhinitis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00581997 | Dec 2007 → Apr 2009 | pulmonary systemic sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00532233 | Sep 2007 → Jun 2009 | idiopathic pulmonary fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02494206 | Jul 2015 → May 2018 | breast cancer, lymphedema | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00940160 Comparator | Jul 2009 → Jan 2010 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01022970 Comparator | Nov 2009 → Feb 2012 | eosinophilic esophagitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QAX576 | “A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease” NCT01316601 ↗14“they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.” NCT02494206 ↗ “The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.” NCT01479595 ↗ |
| Known as | Dectrekumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109465 ↗ |
| Action | Inhibit | “Intravenous anti-IL-13 mAb QAX576” PMID 25226850 ↗ Sep 2014 |
| Modality | Monoclonal antibody | “QAX576 (an interleukin-13 monoclonal antibody)” NCT00584584 ↗ |
| Route | Intravenous | “individual escalating intravenous doses of QAX576” NCT00417196 ↗ |
| Target | IL13 | “an mAb against IL-13” PMID 25226850 ↗ Sep 2014 |